NCT04986605 is a Phase 2 clinical trial of Extracorporeal Photopheresis (ECP) in Diffuse Cutaneous Systemic Sclerosis, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's.

What drugs are being tested in NCT04986605?

Interventions in NCT04986605: Extracorporeal Photopheresis (ECP), UVADEX.

What condition does NCT04986605 study?

NCT04986605 studies Diffuse Cutaneous Systemic Sclerosis.

Is NCT04986605 still recruiting?

NCT04986605 is currently not yet recruiting. Last updated 10 March 2025.

Last reviewed 2025-03-10 · How we verify

NCT04986605

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effectiveness of ECP in Diffuse Cutaneous Systemic Sclerosis

Not yet recruiting Phase 2 Last updated 10 March 2025

What this trial tests

Phase 2 trial testing Extracorporeal Photopheresis (ECP) in Diffuse Cutaneous Systemic Sclerosis in 15 participants. Not yet recruiting.

Timeline

1 July 2025

Primary endpoint
1 July 2026

1 July 2027

Quick facts

Lead sponsor	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	1 July 2025
Primary completion	1 July 2026
Estimated completion	1 July 2027
Sites	1 location across Canada

Drugs / interventions tested

Extracorporeal Photopheresis (ECP) — full drug profile →
UVADEX — full drug profile →

Conditions studied

Diffuse Cutaneous Systemic Sclerosis — all drugs for Diffuse Cutaneous Systemic Sclerosis →

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Who can join

18 and older, any sex, with Diffuse Cutaneous Systemic Sclerosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in skin thickness measured by modified Rodnan Skin Score
Time frame: 48 weeks
modified Rodnan Skin Score (mRSS): is a standard outcome measure for skin disease in SSc and calculated by measuring skin thickness in 17 different body sites (each site scored 0-3, with a total possible additive score of 51). A higher skin score (or a higher "skin thickness") and progression of this score, is predictive of internal organ involvement and mortality. While a lower or improving (less

Sponsor's own description

The purpose of this study is to assess feasibility, safety and preliminary efficacy of Extracorporeal Photopheresis in the treatment of active diffuse cutaneous systemic sclerosis (dcSSc). This pilot study will help to determine if further study (a RCT) is justified.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Extracorporeal Photopheresis (ECP)

Trials testing the same drug.

NCT04446182 — Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD · Phase 2 · terminated
NCT02524847 — Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory A · Phase 3 · terminated
NCT02322190 — Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of · Phase 2 · terminated

Other recruiting trials for Diffuse Cutaneous Systemic Sclerosis

Currently open trials in the same condition.

NCT06925542 — A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease · Phase 1 · recruiting
NCT06375005 — Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis · Phase 2 · recruiting
NCT06470048 — A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis · Phase 2 · recruiting
NCT05149768 — Open Label Extension Study of Brentuximab Vedotin in Early dcSSc · Phase 2 · recruiting
NCT05270668 — Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With I · Phase 2 · active not recruiting

Other London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's trials

Trials by the same sponsor.

NCT07588711 — Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury · NA · not yet recruiting
NCT07585292 — Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Musculoskeletal Pain in Cerebral Palsy · NA · not yet recruiting
NCT07510906 — Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer · NA · not yet recruiting
NCT03166072 — Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers · NA · not yet recruiting
NCT06035809 — Sensory Motor Arousal Regulation Treatment (SMART) Study · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04986605 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Last refreshed: 10 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04986605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing